Zeltiq fails to stop Clinipro from promoting its fat reduction device
Clinipro says it has been cleared by a Spanish court to continue manufacturing, offering, advertising and marketing the LipoCryo device in Spain without any restriction and without involving any infringement neither for the manufacturer nor for the distributor.
Zeltiq Aesthetics and Massachusetts General Hospital had filed a lawsuit against Clinipro in the Barcelona Mercantile Court alleging that the LipoCryo device infringed their patent. Clinipro says the current ruling means that not only does the device remain on sale in Spain, it also remains on sale in markets outside of the country.
LipoCryo is a device that is designed to provide localised fat reduction as part of a non-invasive procedure. It aims to avoid the traumatic experience of invasive methods such as liposuction and prevent the risk of damage on contiguous tissues that are linked radiofrequency treatment, focalised ultrasound or lasers.